Advances in Preventive Medicine / 2012 / Article / Fig 3

Clinical Study

A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study

Figure 3

(a) Primary endpoint: percentage of patients achieving target LDL-C (<2.0 mmol/L) at 6 weeks (b) Percentage of patients achieving target LDL-C (<2.0 mmol/L) at 12 weeks.
103728.fig.003a
(a)
103728.fig.003b
(b)